Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Rare Biomarkers Specimen Collection And Stabilization Market Valuation Change Between Now And 2029?

In past few years, the market size for rare biomarkers specimen collection and stabilization has experienced a significant expansion. It is expected to increase from $32.01 billion in 2024 to $35.29 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. Factors contributing to the growth during the historic period include the human genome project, escalation in cancer research, investment in pharmaceutical R&D, development in genomics and proteomics, and enhanced data management and bioinformatics.

Significant growth is anticipated in the coming years for the rare biomarkers specimen collection and stabilization market, with projections reaching $51.22 billion in 2029, showcasing a compound annual growth rate of 9.8%. Factors contributing to this growth during the forecast period include the broadening scope of liquid biopsy applications, heightened public awareness and demand, rising use of non-invasive procedures, and the discovery of biomarkers in rare diseases. Major trends during the forecast period will be driven by advances in preservation technology, enhancement in genomic and proteomic analysis, the rising trend of point-of-care testing, standard advancements and regularity, improved data analytics, and AI integration.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

What Growth-Enabling Forces Are Impacting The Rare Biomarkers Specimen Collection And Stabilization Market?

The rise in cancer cases is anticipated to drive the expansion of the rare biomarker specimen collection and stabilization market. Characterized by unrestrained cell proliferation and dissemination, cancer is a term for a range of diseases. Environmental pollutants and lifestyle factors, like smoking and bad dietary habits that aggravate genetic vulnerabilities, attribute to an increase in cancer prevalence. The use of rare biomarker specimen collection and stabilization techniques in cancer prevalence studies allows for more precise recognition and tracking of distinct types of cancer, hence improving diagnostic and therapeutic tactics. For instance, a European Commission report in October 2023 disclosed that there were 2.74 million new cancer cases in 2022, a 2.3% rise from 2020. Therefore, the escalating prevalence of cancer is fueling the expansion of the rare biomarker specimen collection and stabilization market.

What Are The Main Segment Classifications In The Rare Biomarkers Specimen Collection And Stabilization Market?

The rare biomarkers specimen collection and stabilizationmarket covered in this report is segmented –

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA); Circulating Tumor Cells (CTCs); Exosomes or Extracellular Vesicles

2) By Specimen: Serum Or Plasma; Other Specimens

3) By Application: Non-Invasive Prenatal Testing (NIPT); Oncology; Transcriptomics; Pharmacogenomics; Transplant Rejection; Population Screening; Cardiovascular Diseases; Other Applications

4) By End-User: Hospitals; Perinatal Clinics; Public Health Labs; Private Or Commercial Labs; Physician Labs; Research Institutes; Other End-Users

Subsegments:

1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA; Serum CCFDNA

2) By Circulating Tumor Cells (CTCs): CTCs In Blood; CTCs In Bone Marrow

3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma; Exosomes From Serum

How Are Market Trends Influencing Competition In The Rare Biomarkers Specimen Collection And Stabilization Market?

Leading firms in the rare biomarker specimen collection and stabilization market are concentrating on the development of groundbreaking solutions like a pre-analytical platform for automating the process of preparing plasma and cell samples for multiomic liquid biopsy. The pre-analytical platform delivers automated fresh sample preparation immediately during blood collection, which in turn eliminates the need for special tubes and trained professionals, hence securing the sample integrity. In May 2022, for instance, Tethis S.p.A., a biotech firm based in Italy, introduced See.d, which is the first fully automated, standardized pre-analytical platform. It boasts exclusive features such as precise sample manipulation, superior separation of plasma for cell fractions, and the fixation of white blood cells on SmartBioSurface slides. Additionally, the platform includes a quality control assessment system for the objective analysis of sample stability. By doing so, it facilitates systematic scoring of proteomics and metabolomics data sets required for determining the stability of plasma and serum samples.

Which Firms Are Driving Innovation Within The Rare Biomarkers Specimen Collection And Stabilization Market?

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

What Are The Emerging Regional Trends Driving The Rare Biomarkers Specimen Collection And Stabilization Market?

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp

Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2025, By The Business Research Company

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Cancer Biomarker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model